Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

November 14, 2013.  Interested parties can access the replay by dialing 888-843-7419 or 630-652-3042 internationally and entering the conference number 35977176.

The conference call webcast is accessible through the "Investors & Media" section of the Ambit website at http://www.ambitbio.com.  An online replay will be available following the initial broadcast until Saturday, December 7, 2013.  Please visit Ambit's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Ambit's expectations regarding future development and therapeutic potential of quizartinib and Ambit's other drug candidates, progress and timing o
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ... and Chief Executive Officer, will present at the Rodman & ... New York on Tuesday, Sept. 9, 2014 ... archived webcast of the presentation will be accessible by visiting ... Events" section. About Oncothyreon ...
(Date:9/2/2014)... , September 2, 2014 ... BioData,s research and lab management services  BioData, ... service, is pleased to announce the appointment of ... most recently served as VP Marketing and Business Development ... science research and clinical applications. Previously, Culot ...
(Date:8/31/2014)... Aug. 31, 2014 Wockhardt Limited today announces ... in Anti-Infective research when two of its drugs, WCK ... Disease Product (QIDP) status from U.S. Food & Drug ... act against pathogens which have a high degree of ... Centre for Disease Control (a top U.S. government health ...
(Date:8/29/2014)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... and difficult to manufacture proteins including biosimilar therapeutics, ... results for the second quarter ended June 30, ... our initial public offering, we have the capital ... derived from our proprietary protein expression platform," stated ...
Breaking Biology Technology:Louis Culot Appointed as BioData's CEO 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8
... Veeramani, director of the E-Business Institute. Madison, Wis. ... new world of advertising, says Jerry Shereshewsky, ambassador plenipotentiary to ... student (and cohort of former Madison Mayor Paul Soglin) during ... the future of business. He was a Russian history major, ...
... are located in the MG&E Innovation Center at University ... research group ConjuGon announced on Tuesday that ... dollars from angel investors, including the firm Wisconsin ... to the firms operating costs, as well as financing ...
... gets $95,000 to help small businesses TeraMedica scans ... make deadly disease Platypus plans office move next ... UW students use more mobile computing ... implement Fiserv's ExchangeGuard , UW-Extension gets ...
Cached Biology Technology:Advertising ambassador explains the reinvention of marketing 2Advertising ambassador explains the reinvention of marketing 3ConjuGon lands $1 million angel investment 2Tech Digest: whats moving in the Midwest 2Tech Digest: whats moving in the Midwest 3
(Date:9/2/2014)... 2, 2014 A study published in the ... the American Academy of Child and Adolescent Psychiatry ... a psychiatric diagnosis had an increased risk of ... , Using data from the nationwide Danish registers, ... Ernst Nielsen, Psychiatry, Aalborg University Hospital, Denmark, studied ...
(Date:9/2/2014)... spiky legs and their propensity for eating anything, including ... And now research from North Carolina State University finds ... across the eastern United States. , "The good news ... kind of threat to humans," says Dr. Mary Jane ... author of a paper about the research. , The ...
(Date:9/2/2014)... stress in stride; others are done in by it. ... mechanisms of this so-called stress gap in mice with ... lead researchers to better understand the development of psychiatric ... each animal has unique experiences as it goes through ... can alter the expression of genes, and as a ...
Breaking Biology News(10 mins):Risk of diabetes in children and adolescents exposed to antipsychotics 2Researchers find Asian camel crickets now common in US homes 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3
... perspective, the answer is not as obvious as one might ... American Naturalist suggests that sex may have evolved ... central role in biology, sex is a bit of an ... a few reptileswould seem like a better way to go. ...
... emerging field of synthetic biology uses engineering techniques to ... systems or even engineer new life forms. Though these ... and applications for human health, they also raise a ... A symposium to be held by the U.S. ...
... pilot study that re-conceptualized the hospital labour room by removing ... ,28 per cent drop in infusions of artificial oxcytocin, a ... study, called PLACE (Pregnant and Labouring in an Ambient Clinical ... Birth . In addition, more than 65 ...
Cached Biology News:Study finds role for parasites in evolution of sex 2Laboring without the labor bed: It's a good thing 2
...
... DEPC-treated Water is suitable for ... prepared by incubating with 0.1% ... to remove the DEPC.DNase/RNase-Free Distilled ... use in all molecular biology ...
IHC detection kit for BrdU in cells and tissues...
Immunogen: Human Respiratory Syncytial Virus (RSV) and Bovine Respiratory Syncytial Virus (BRSV) Fusion protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: